中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2013年
5期
341-346
,共6页
杨佩%冯小伟%叶兆祥%李绪斌%侯岩%刘义涛%肖建宇
楊珮%馮小偉%葉兆祥%李緒斌%侯巖%劉義濤%肖建宇
양패%풍소위%협조상%리서빈%후암%류의도%초건우
VX2软组织肿瘤%体层摄影术,X线计算机%血管生成抑制剂%血流量%血容量%平均通过时间%表面通透性
VX2軟組織腫瘤%體層攝影術,X線計算機%血管生成抑製劑%血流量%血容量%平均通過時間%錶麵通透性
VX2연조직종류%체층섭영술,X선계산궤%혈관생성억제제%혈류량%혈용량%평균통과시간%표면통투성
Soft tissue tumor,VX2%Tomography,X-ray computer%Angiogenesis inhibitors%Blood flow%Blood volume%Mean transit time%Permeability
目的 探讨CT容积灌注成像的动态监测及其评估兔VX2软组织肿瘤抗血管生成治疗反应的可行性.方法 建立20只兔VX2软组织肿瘤模型,随机分为治疗组和对照组.治疗组给予重组人血管内皮抑制素3mg·kg-1 ·d-1,连续治疗7d;对照组给予同等剂量的生理盐水.于治疗前和治疗第2、4、7天行CT容积灌注扫描,获取肿瘤灌注参数血流量(BF)、血容量(BV)、平均通过时间(MTT)和表面通透性(PMB).采用免疫组化法检测肿瘤微血管密度(MVD)和血管内皮生长因子(VEGF)的表达.结果 治疗第4、7天时,治疗组的肿瘤体积分别为(1.36±0.73) cm3和(1.69±0.68) cm3,对照组分别为(2.35±0.62) cm3和(3.87±0.93) cm3(均P ＜0.05).治疗第7天时,治疗组和对照组的肿瘤坏死率分别为(25.58±5.51)％和(42.93±4.34)％(P＜0.05).两组同一治疗时间点灌注参数比较显示,治疗第2、4、7天时,治疗组的PMB值分别为(70.36±23.46)ml·100 ml-1·min-1、(79.64±13.68)ml·100 ml-1·min-1和(84.76 ±3.55)ml·100 ml-1·min-1,对照组分别为(26.61 ±6.47)ml· 100 m1-1·min-1、(33.74±16.47)ml·100 ml-1·min-1和(30.47±10.64)ml· 100 ml-1·min-1(均P＜0.05)；治疗第7天时,治疗组和对照组的BF值分别为(71.19±12.21)ml·100 ml-1·min-1和(43.56±12.21)ml· 100ml-1·min-1 (P ＜0.05).组内不同治疗时间点的两两比较显示,对照组治疗第7天的BF值明显低于治疗前和治疗第2、4天(P＜0.05)；治疗组治疗后各时间点的PMB值均高于治疗前(P＜0.05).对照组MVD随治疗时间的增加逐渐增多,而治疗组MVD呈先增多再下降的趋势.对照组和治疗组的VEGF表达均为强阳性,无明显差异.结论 CT容积灌注能够量化评估软组织肿瘤血流灌注量及其血管功能状态的改变,进而评价抗血管生成治疗的早期疗效.
目的 探討CT容積灌註成像的動態鑑測及其評估兔VX2軟組織腫瘤抗血管生成治療反應的可行性.方法 建立20隻兔VX2軟組織腫瘤模型,隨機分為治療組和對照組.治療組給予重組人血管內皮抑製素3mg·kg-1 ·d-1,連續治療7d;對照組給予同等劑量的生理鹽水.于治療前和治療第2、4、7天行CT容積灌註掃描,穫取腫瘤灌註參數血流量(BF)、血容量(BV)、平均通過時間(MTT)和錶麵通透性(PMB).採用免疫組化法檢測腫瘤微血管密度(MVD)和血管內皮生長因子(VEGF)的錶達.結果 治療第4、7天時,治療組的腫瘤體積分彆為(1.36±0.73) cm3和(1.69±0.68) cm3,對照組分彆為(2.35±0.62) cm3和(3.87±0.93) cm3(均P ＜0.05).治療第7天時,治療組和對照組的腫瘤壞死率分彆為(25.58±5.51)％和(42.93±4.34)％(P＜0.05).兩組同一治療時間點灌註參數比較顯示,治療第2、4、7天時,治療組的PMB值分彆為(70.36±23.46)ml·100 ml-1·min-1、(79.64±13.68)ml·100 ml-1·min-1和(84.76 ±3.55)ml·100 ml-1·min-1,對照組分彆為(26.61 ±6.47)ml· 100 m1-1·min-1、(33.74±16.47)ml·100 ml-1·min-1和(30.47±10.64)ml· 100 ml-1·min-1(均P＜0.05)；治療第7天時,治療組和對照組的BF值分彆為(71.19±12.21)ml·100 ml-1·min-1和(43.56±12.21)ml· 100ml-1·min-1 (P ＜0.05).組內不同治療時間點的兩兩比較顯示,對照組治療第7天的BF值明顯低于治療前和治療第2、4天(P＜0.05)；治療組治療後各時間點的PMB值均高于治療前(P＜0.05).對照組MVD隨治療時間的增加逐漸增多,而治療組MVD呈先增多再下降的趨勢.對照組和治療組的VEGF錶達均為彊暘性,無明顯差異.結論 CT容積灌註能夠量化評估軟組織腫瘤血流灌註量及其血管功能狀態的改變,進而評價抗血管生成治療的早期療效.
목적 탐토CT용적관주성상적동태감측급기평고토VX2연조직종류항혈관생성치료반응적가행성.방법 건립20지토VX2연조직종류모형,수궤분위치료조화대조조.치료조급여중조인혈관내피억제소3mg·kg-1 ·d-1,련속치료7d;대조조급여동등제량적생리염수.우치료전화치료제2、4、7천행CT용적관주소묘,획취종류관주삼수혈류량(BF)、혈용량(BV)、평균통과시간(MTT)화표면통투성(PMB).채용면역조화법검측종류미혈관밀도(MVD)화혈관내피생장인자(VEGF)적표체.결과 치료제4、7천시,치료조적종류체적분별위(1.36±0.73) cm3화(1.69±0.68) cm3,대조조분별위(2.35±0.62) cm3화(3.87±0.93) cm3(균P ＜0.05).치료제7천시,치료조화대조조적종류배사솔분별위(25.58±5.51)％화(42.93±4.34)％(P＜0.05).량조동일치료시간점관주삼수비교현시,치료제2、4、7천시,치료조적PMB치분별위(70.36±23.46)ml·100 ml-1·min-1、(79.64±13.68)ml·100 ml-1·min-1화(84.76 ±3.55)ml·100 ml-1·min-1,대조조분별위(26.61 ±6.47)ml· 100 m1-1·min-1、(33.74±16.47)ml·100 ml-1·min-1화(30.47±10.64)ml· 100 ml-1·min-1(균P＜0.05)；치료제7천시,치료조화대조조적BF치분별위(71.19±12.21)ml·100 ml-1·min-1화(43.56±12.21)ml· 100ml-1·min-1 (P ＜0.05).조내불동치료시간점적량량비교현시,대조조치료제7천적BF치명현저우치료전화치료제2、4천(P＜0.05)；치료조치료후각시간점적PMB치균고우치료전(P＜0.05).대조조MVD수치료시간적증가축점증다,이치료조MVD정선증다재하강적추세.대조조화치료조적VEGF표체균위강양성,무명현차이.결론 CT용적관주능구양화평고연조직종류혈류관주량급기혈관공능상태적개변,진이평개항혈관생성치료적조기료효.
Objective To explore the feasibility of volume perfusion CT imaging to dynamically monitor and evaluate the response of rabbit VX2 soft-tissue tumor to antiangiogenic treatment.Methods To establish an experimental animal model of VX2 soft tissue tumor on 20 New Zealand white rabbits.Twenty rabbits were randomly divided into 2 groups.The therapy group was treated with recombinant human endostatin (3 mg· kg-1 · d-1) for 7 days,and the control group received saline in the same dose only.Four times of CT volume perfusion scan were performed before treatment and on the second,forth,seventh days of treatment,respectively.The value of blood flow (BF),blood volume (BV),mean transit time (MTT),and permeability (PMB) in the VX2 tumors were measured after scanning.The microvessel density (MVD) and expression of vascular endothelial growth factor (VEGF) in the tumors were determined using immunohistochemical staining.Results The tumor volume of the therapy group was (1.36 ± 0.73)cm3 on the forth day of treatment and (1.69 ± 0.68) cm3 on the seventh day of the treatment.The tumor volume of the control group was (2.35 ± 0.62) cm3 on the fourth day of treatment and (3.87 ± 0.93) cm3 on the seventh day of the treatment (P ＜ 0.05).On the seventh day of treatment,tumor necrosis ratio of the therapy group and the control group was (25.58 ± 5.51) ％ and (42.93 ± 4.34) ％,respectively (P ＜0.05).Comparing the perfusion parameters between the two groups on the same day,and the second,forth,seventh days of treatment,the value of PMB of the therapy group was (70.36 ±23.46) ml · 100 ml-1 · min-1,(79.64 ±13.68) ml · 100 ml-1 · min-1 and (84.76 ±3.55) ml · 100 ml-1 · min-1,respectively,and that in the control group was (26.61 ±6.47) ml · 100 m1-1 · min-1,(33.74±16.47) ml · 100 ml-1 · min-1 and (30.47 ± 10.64) ml · 100 ml-1 · min-1,respectively (P＜0.05).The value of BF in the therapy group and control group was (71.19 ± 12.21) ml · 100 ml-1 · min-1 and (43.56 ± 12.21) ml · 100 ml-1 · min-1,respectively,on the seventh day of treatment (P ＜ 0.05).The parameters on different days in the same group were compared.In the control group,the value of BF on the seventh day of treatment was significantly lower than that before and on the second and forth days of treatment (P ＜ 0.05).However,in the therapy group,the value of PMB on the second,forth,and seventh days of treatment was significantly higher than that before treatment (P ＜ 0.05).MVD of tumor in the control group was increased gradually,whereas increased on the first day and then decreased more in the therapy group.The VEGF expressions did not differ significantly between the experimental and control groups.Conclusions Volume perfusion CT is helpful to quantify the tumor perfusion and evaluate the functional changes of tumor vasculature,and then evaluate the early therapeutic effect of antiangiogenic treatment.
